Advancing novel therapies to restore the health of gastrointestinal tissues
About us
Transforming GI tissue regeneration
Curileum is developing novel therapies that restore the health of gastrointestinal (GI) tissues, intervening early in disease development to prevent bowel cancer and treat inflammatory bowel disease (IBD).
Our products
Developing novel theories
Partnering
Partnered with industry leaders
We collaborate with leading industrial and academic institutions, providing state-of-the-art expertise to efficiently progress early-stage research.
Based adjacent to St Mark’s Hospital in London, one of the world’s only GI-dedicated hospitals, we are embedded in an ecosystem of treating gastrointestinal disease.
We partner with experts in drug synthesis and pre-clinical studies to produce high-quality, reliable data that accelerates and supports its pipeline.
Investors
Why Curileum?
Backed by over 40 years of drug discovery, the Curileum team has secured over $20m to advance novel GI therapies through to late-stage preclinical development and is raising £5m for a first-in-human clinical study in FAP patients starting in 2026.
Our team
Guided by experts
Curileum is backed by over 40 years of drug discovery, targeting diseases in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa.
Its team has raised over $20m to advance novel GI therapies through to late-stage preclinical development.
